Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Q3 FY25 Earnings Presentation
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation for the quarter and half year ended 30th September, 2024
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation for the quarter ended 30th June, 2024
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investors Presentation on the Audited Financial Results for the quarter and year ended 31st Match, 2024
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation for the quarter and nine months ended December 31, 2023
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation on Q2FY24 Results
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation for the Quarter ended 30th June 2023
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation for the quarter and year ended 31st March, 2023
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation for the quarter and nine months ended 31st December, 2022